XKEM went to heaven in 2011 
XKEM has been revoked from any trading, per the Securities and Exchange Commission. SECURITIES EXCHANGE ACT OF 1934
Release No.
66613/March 16, 2012
ADMINISTRATIVE PROCEEDING
File No. 3-14732
http://www.sec.gov/litigation/admin/2012/34-66613.pdf All assets were sold at auction, and all operations have ceased. "
On October 7, 2011, the 'Q' was removed from the trading symbol of XKEMQ.PK changing it to XKEM.PK. The "Q" designation is used to indicate reorganization under the Bankruptcy Code. On August 24, 2011, all right, title, and interest to any and all assets of Xechem International, Inc. (the "Company") and Xechem, Inc. where sold at auction, including any and all right, title and interest to Xechem (India) Pvt. Limited and Xechem Pharmaceuticals Nigeria Limited. For further information, see case no. 08-30512 in the United States
Bankruptcy Court, Northern District of Illinois (Eastern Division)." SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934
Date of Report: October 10, 2011
(Date of earliest event reported)
XECHEM INTERNATIONAL, INC.
(Exact name of registrant as specified in the charter)
| Delaware | 0-23788 | 22-3284403 |
| (State or other jurisdiction of incorporation) | (Commission File No.) | (IRS Employer Identification No.) |
1550 Main Street, Suite A3
Windsor, CO 80550
(Address of Principal Executive Offices)
(970) 377-9554
Registrant's telephone number including area code)
New Brunswick Technology Center
100 Jersey Avenue, Building B, Suite 310
New Brunswick, New Jersey 08901-3279
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| £ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| £ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| £ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| £ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 8 - Other Events
Item 8.01 Other Events
Change of trading Symbol
On October 7, 2011, the 'Q' was removed from the trading symbol of XKEMQ.PK changing it to XKEM.PK. The "Q" designation is used to indicate reorganization under the Bankruptcy Code. On August 24, 2011, all right, title, and interest to any and all assets of Xechem International, Inc. (the "Company") and Xechem, Inc. where sold at auction, including any and all right, title and interest to Xechem (India) Pvt. Limited and Xechem Pharmaceuticals Nigeria Limited. For further information, see case no. 08-30512 in the United States Bankruptcy Court, Northern District of Illinois (Eastern Division).
Xechem International, Inc. and Ministry of Health, Federal Republic of Nigeria .
In July 2002 the Company formed Xechem Pharmaceuticals Nigeria Limited ("Xechem
Nigeria"). On July 18, 2002, the Company signed an exclusive worldwide license agreement (the "Agreement") with the National Institute of Pharmaceutical Research and Development (Federal Ministry of Health) the Federal Republic of Nigeria, for the manufacture, marketing, distribution and sales of NIPRISAN(TM), a botanical (the "Botanical") for the treatment of Sickle Cell Disease. The Minister of Health, A.B.C. Nwosu, signed the Agreement in his capacity as Minister of Health of Nigeria.
The Agreement stated there were "…related patents and foreign counterpart patents thereof, and totaling forty-six (46) patents world-wide….", and the Licensor warranted that "… LICENSED PATENTS are, each and every one, valid and enforceable in their respective jurisdictions, and that LICENSOR has maintained and shall maintain the validity and enforceability of the said PATENT RIGHTS for the term of this AGREEMENT."
Documents filed during the Bankruptcy proceedings of the Company disclosed licensed patents had been abandoned, and were no longer valid and enforceable, before the Agreement was signed on July 18, 2002, and therefore there were not "forty-six (46) patents world-wide" , as the Agreement stated, when the Agreement was signed on July 18, 2002. The Company paid licensing fees and royalty payments to the National Institute of Pharmaceutical Research and Development, and the Company invested substantial sums of money in the development of the Botanical, all under written representations contained in the Agreement signed by The Minister of Health, A.B.C. Nwosu, in his capacity as Minister of Health of Nigeria.
| Item 9.01 | Financial Statements and Exhibits. |
None
None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | |
| | | | | XECHEM INTERNATIONAL, INC. |
| | | | |
| Date: October 17, 2011 | | | | By: | | /s/ Stephen F Burg |
| | | | | Name: | | Stephen F Burg |
| | | | | Title: | | Corporate Secretary |
http://sec.gov/litigation/suspensions/2012/34-66297.pdf U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
SECURITIES EXCHANGE ACT OF 1934 Release No. 66297 / February 2, 2012
The U.S. Securities and Exchange Commission announced the temporary suspension of trading in the securities of the following issuers, commencing at 9:30 a.m. EST on February 2, 2012 and terminating at 11:59 p.m. EST on February 15, 2012: American Unity Investments, Inc. (AUNI)
China Display Technologies, Inc. (CDYT)
China Wind Energy, Inc. (CWEY)
Fuda Faucet Works, Inc. (FUFW)
Greater China Media & Entertainment Corp. (GTCN)
Xechem International, Inc. (XKEM) The Commission temporarily suspended trading in the securities of the foregoing companies due to a lack of current and accurate information about the companies because they have not filed certain periodic reports with the Commission. This order was entered pursuant to Section 12(k) of the Securities Exchange Act of 1934 (Exchange Act).
The Commission cautions brokers, dealers, shareholders and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by these companies.
Brokers and dealers should be alert to the fact that, pursuant to Exchange Act Rule 15c2-11, at the termination of the trading suspensions, no quotation may be entered relating to the securities of the subject companies unless and until the broker or dealer has strictly complied with all of the provisions of the rule. If any broker or dealer is uncertain as to what is required by the rule, it should refrain from entering quotations relating to the securities of these companies that have been subject to trading suspensions until such time as it has familiarized itself with the rule and is certain that all of its provisions have been met. Any broker or dealer with questions regarding the rule should contact the staff of the Securities and Exchange Commission in Washington, DC at (202) 551-5720. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action.
If any broker, dealer or other person has any information which may relate to this matter, they should immediately contact Ansu N.
